GM-5022
GM-5022 is a non-hallucinogenic psychoplastogen which is under development for the treatment of depressive, anxiety, and other neurological disorders. It is taken orally. The drug's specific mechanism of action and chemical structure do not appear to have been disclosed yet. GM-5022 is under development by Gilgamesh Pharmaceuticals. As of December 2024, it is in the preclinical research stage of development, with an Investigational New Drug application being worked on.